Teva Pharmaceutical Industries launched its Adasuve inhaled powder for the treatment of agitation associated with schizophrenia and bipolar I disorder in the U.S. The drug is the first of its kind with this delivery system, which uses Alexza Pharmaceuticals' Staccato device for absorption in the lungs.
Teva doesn't have much time left to switch patients over to its new, thrice-weekly Copaxone injection before generics jump on the current product. And while the company is working feverishly to market its new drug to patients, insurers may be the most difficult to persuade.
European regulatory authorities gave Teva a positive opinion for its DuoResp Spiromax inhalation powder, designed to treat asthma and chronic obstructive pulmonary disease. With the recommendation from the Committee for Medicinal Products for Human Use, Teva hopes to have final approval within a few months.
At least one key investor seems to think Teva is headed in the right direction. Billionaire George Soros boosted his family office's stake in the Israeli company in the last quarter of 2013, adding 5.7 million shares to make the Israeli generics giant its largest holding.
If Big Pharma should consider hiving off extraneous business units, then why not Big Generics? Goldman Sachs analyst Jami Rubin, an early champion of the pharma breakup, figures Teva Pharmaceutical Industries could try it.
Teva Pharmaceutical Industries is like a skiff-racing team that's beating its own speed records on the river but heading for an enormous waterfall just around the bend. As well as it performs now, the question remains: How well can it recover from the imminent loss of Copaxone patent protection?
Teva Pharmaceutical Industries, which has been tightening its supply chain and manufacturing network, turned in better-than-expected earnings for its fourth quarter.
Regulators in Europe refused to give a favorable review to laquinimod, a potential successor treatment to Teva's multiple sclerosis drug Copaxone, which faces generic competition in May.
The European Medicines Agency will take a deep dive into whether over-the-counter emergency contraceptives--the so-called "morning-after pill"--don't work well in heavier women. It will review a handfull of the approved products in Europe. The FDA is doing the same with the Plan-B drug sold in the U.S. by Teva Pharmaceutical Industries.
It looks as if Teva Pharmaceutical Industries is taking its shareholders' concerns to heart. Just a few weeks after activist investor Benny Landa rallied support for a boardroom overhaul, Teva has promised to effect some changes: namely, cutting down the size of the board while upping the experience level.